Argipressin's Influence on Blood Loss During Hepatic Resection

Status Recruiting

Clinical Trial Summary

Infusion of Argipressin during hepatic resection surgery may reduce blood loss. It may also reduce transfusion requirements, and mitigate the perioperative inflammatory response compared to placebo. Subjects will be randomized to infusion of Argipressin or placebo during surgery. Blood loss, transfusion requirements, surgical data including length of stay in hsopital, inflammatory markers and markers of renal- intestinal- and cardiac injury will be assessed.

Clinical Trial Description

Hepatic resection is a major surgical intervention with high risk of substantial blood loss. The surgical means to reduce blood loss may impair perfusion and induce intestinal congestion. If blood flow to the liver can be influenced by pharmacological means, blood loss and transfusion requirements may be reduced. Moreover, the inflammatory system is involved in cancer development, and the anti-inflammatory properties of Argipressin may decrease the inflammatory response after hepatic surgery. Argipressin is an endogenous substance, and part of the body's response to stress and trauma. Argipressin affects V1-receptors to produce vasoconstriction. It is also involved in inflammatory reactions and affects platelets. Patients will be stratified according to planned type of surgery (open/laparoscopic) and planned extent of resection, and randomized to etiher infusion of Argipressin or placebo (normal saline) during surgery. In all other aspects, the participants will be treated according to the institution protocol for hepatic resection. The study drug will be started as soon as the central line is placed, and discontinued at the end of surgery. Hemodynamic data will be collected during surgery, and blood and urine-samples will be obtained during and after surgery for analysis of inflammatory markers and markers of organ injury. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05293041
Study type	Interventional
Source	Sahlgrenska University Hospital, Sweden
Contact	Ellinor Wisen, MD
Phone	+46313428171
Email	ellinor.wisen@vgregion.se
Status	Recruiting
Phase	Phase 4
Start date	March 27, 2022
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04496154` - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood	N/A
Not yet recruiting	`NCT06434701` - Severe COVID-19 Infection in Children Presenting to EDs in Israel and England	N/A
Enrolling by invitation	`NCT05020210` - Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
Completed	`NCT04084301` - Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury	N/A
Completed	`NCT04597983` - Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists	N/A
Not yet recruiting	`NCT06016023` - Evaluation of Macrophage Inflammatory Protein-1α as a Periodontal Disease Biomarker
Not yet recruiting	`NCT05990933` - Role of Adrenaline in in the Inflammatory Response in Diabetes	N/A
Not yet recruiting	`NCT04608643` - Inflammatory Markers and Cbc Indices in Severely Malnourished Children
Recruiting	`NCT01934049` - Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty	Phase 4
Recruiting	`NCT01417923` - The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain	Phase 4
Terminated	`NCT01377441` - Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia.	Phase 4
Completed	`NCT01301079` - Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia	Phase 3
Terminated	`NCT00578578` - Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels	Phase 4
Recruiting	`NCT04611334` - The Effects of HRV Biofeedback on Chronic Kidney Disease Patient.	N/A
Recruiting	`NCT03510702` - SCREENING OF EPIGENETIC BIOMARKERS (miRNAs) IN THE GINGIVAL SULCUS
Completed	`NCT03445234` - Blueberries, Bananas, Exercise Recovery	N/A
Not yet recruiting	`NCT06450704` - Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders	N/A
Not yet recruiting	`NCT05754294` - Electric Polarization of Red Blood Cells : A Cohort Study to Assess the Erythrocytes Membrane Integrity Through Charge Conservation, Following Cardiac Surgery.
Completed	`NCT04864600` - CANDLE - A Study of Acute Health Effects of Exposure to Particles Generated by Candles	N/A
Not yet recruiting	`NCT04386525` - Omega 3 and Ischemic Stroke; Fish Oil as an Option	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Argipressin's Influence on Blood Loss During Hepatic Resection — ARG-01

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms